

Optomed Q3 - In line with the expectations

Redeye provides an update following Optomed's Q3 report. Sales and EBIT were on the soft side; however, this was fairly in line with our expectations as the company decreased its full-year outlook during the quarter. Based on the report, we have only made minor estimate changes, which do not affect our fair value range.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Optomed Q3 - In line with the expectations